ZIAGEN

Compare ZIAGEN  to:
Compare
Compare

Generic Name for ZIAGEN

Abacavir (as sulfate) 300mg; tabs.

Legal Classification:

Rx

Pharmacological Class for ZIAGEN

Nucleoside analogue (reverse transcriptase inhibitor).

Manufacturer of ZIAGEN

GlaxoSmithKline Pharmaceuticals

Indications for ZIAGEN

HIV-1 infection.

Adult dose for ZIAGEN

>16 years: 300mg twice daily or 600mg once daily. Mild hepatic impairment: 200mg twice daily.

Children's dosing for ZIAGEN

<3 months: not recommended. ≥3 months–16 years: 8mg/kg twice daily; max 300mg twice daily.

Also:

Contraindications for ZIAGEN

See literature regarding fatal hypersensitivity reactions (which may include fever, rash, fatigue, nausea, vomiting, diarrhea, abdominal pain, or respiratory symptoms); discontinue as soon as suspected; do not restart, regardless of HLA-B*5701 status. Moderate or severe hepatic impairment.

Warnings/Precautions for ZIAGEN

Evaluate for presence of HLA-B*5701 allele prior to starting therapy or reinitiation; if positive, abacavir is not recommended; discontinue permanently if hypersensitivity cannot be ruled out. Decompensated liver disease or risk factors for liver disease. Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Cardiovascular disease. Smoking. Women, obesity, prolonged nuceloside exposure: increased risk of toxicity. Do not add as a single agent to a failing regimen. If stopped for reasons other than hypersensitivity, restart only if medical care can be readily accessed by patient or caregiver. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for ZIAGEN

May antagonize methadone. May be potentiated by ethanol. Triple therapy (once daily regimen) with lamivudine + tenofovir: high rate of early viral non-response (see literature).

Adverse Reactions for ZIAGEN

Nausea, vomiting, headache, malaise, fatigue, dreams/sleep disorders, diarrhea, fever, rash (may be severe, eg, Stevens-Johnson), ear/nose/throat infections, mild hyperglycemia, elevated triglycerides, pancreatitis; hypersensitivity reactions (may be fatal); lactic acidosis, severe hepatomegaly with steatosis, immune reconstitution syndrome, fat redistribution.

Notes for ZIAGEN

Register pregnant patients exposed to abacavir by calling (800) 258-4263. Register patients who have had a hypersensitivity reaction to abacavir by calling (800) 270-0425.

How is ZIAGEN supplied?

Tabs—60
Soln—240mL

Related Disease:

HIV~antivirals

Related Resources

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions